Oncolines – Case Studies

Oncolines is a daughter company of Symeres. Oncolines B.V. was founded in 2021 as a spin-off company of Netherlands Translational Research Center B.V. (NTRC), a biotech company established in Oss (The Netherlands) in 2011 by former employees of Organon/MSD.

Oncolines is named after its large cancer cell line panel (the Oncolines® panel) and its cell line proliferation assay and bioinformatics services.

Reproducible Results, Short Timelines, Swift Communications

We provide high quality results with a short delivery time. Direct contact between our staff and sponsors results in efficient scientific and technical support. We provide cost-free consultation on next steps in research if desired by the sponsor.

Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors

Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors

Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors

Oncolines®2024-11-19T13:49:33+01:00

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

janneke2024-11-19T13:00:16+01:00

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Oncolines®2024-11-19T11:37:24+01:00

Oncolines Casestudy Target Identification Via Oncolines® Profiling And ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Oncolines®2024-11-19T13:47:41+01:00

Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

janneke2024-11-19T11:59:34+01:00

Case study – Combination matrix to determine Bliss independence synergy scores

Case study – Combination matrix to determine Bliss independence synergy scores

Case study – Combination matrix to determine Bliss independence synergy scores

Oncolines®2024-11-19T11:39:02+01:00

Case study – 3D spheroid drug sensitivity

Case study – 3D spheroid drug sensitivity

Case study – 3D spheroid drug sensitivity

yvonne2024-11-19T13:05:49+01:00

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Oncolines®2024-11-19T12:03:15+01:00

Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Oncolines®2024-11-19T13:41:57+01:00

Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Oncolines®2024-11-19T12:51:07+01:00